Breaking Health News: FDA Approves Drug for Rare Heart Condition and More

The U.S. FDA approved BridgeBio's drug for a rare heart condition. Researchers found cancer features in healthy breast cells. Canada confirms its first clade I mpox case. A neurosurgery trial involves Musk's Neuralink. The WHO continues the mpox emergency. The US CDC confirms H5N1 bird flu in a child.

In pivotal developments within the health sector, BridgeBio announced FDA approval for its drug targeting transthyretin amyloid cardiomyopathy (ATTR-CM), a rare heart condition.

Meanwhile, Canadian physicians confirmed the country's first case of clade I mpox, pointing to an outbreak linked to Africa. WHO also maintains a public health emergency status for this disease.

Additionally, a novel trial involving Neuralink seeks patients for groundbreaking neuro-experiments, as concerns loom over a widely used asthma drug's mental effects, and the CDC confirms H5N1 bird flu in a California child.

(With inputs from agencies.)